Effect of interleukin-2 on the ex vivo growth of human myeloma cells.
Short-term cultures containing bone marrow mononuclear cells from multiple myeloma patients secrete monoclonal immunoglobulin- and beta 2-microglobulin into the supernatant, which can be measured quantitatively in an enzyme-linked immunosorbant assay. In this system, the addition of interleukin-2 was shown to induce tumor cell regression in the cultures from 10 out of 14 multiple myeloma patients in a dose-dependent manner. Marker analyses of culture cell populations indicate that OKT3 antibody or interleukin-2 did not directly act on the malignant clone but augmented autologous T lymphocytes, which were responsible for the regression of tumor cells in the cultures.
Peest
D
D
Abteilung Immunologie und Transfusionsmedizin, Medizinische Hochschule Hannover, Federal Republic of Germany.
de Vries
I
I
Hölscher
R
R
Leo
R
R
Deicher
H
H
D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D001853:Bone Marrow / Q000187:drug effects; D017252:CD3 Complex; D006801:Humans; D007136:Immunoglobulins / Q000096:biosynthesis; D007376:Interleukin-2 / Q000494:pharmacology* / Q000627:therapeutic use; D008213:Lymphocyte Activation / Q000187:drug effects; D009101:Multiple Myeloma / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D011948:Receptors, Antigen, T-Cell / Q000032:analysis; D011994:Recombinant Proteins / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D007136:Immunoglobulins; D007376:Interleukin-2; D011948:Receptors, Antigen, T-Cell; D011994:Recombinant Proteins